Market Newsdesk

KANSAS CITY, Mo., Oct. 28, 2021 (GLOBE NEWSWIRE) — H&R Block, Inc. (NYSE: HRB) and The Urban League of Greater Kansas City announced today the distribution of five micro-grants among the first cohort of Black business owners participating in the first year of the new small business program provided in partnership by the two organizations.

The program supports Black-owned businesses, helping them survive and thrive as part of H&R Block’s goal of reaching and supporting 500,000 small business owners by 2025. Block Advisors small business certified tax pros provide free one-on-one coaching designed to improve financial management, tax compliance, bookkeeping and payroll; ultimately increasing business owners’ confidence when seeking financial capital and helping to foster equitable communities. The Urban League also provided free credit-building services and other business coaching, as needed.

The five business owners who are receiving micro-grants that align with their personalized, business coaching goals are:

• 
  5515 LLC Roofing & Construction
  
  , to purchase new equipment for roof inspections.
• 
  Anna’s BLD Restaurant & Catering
  
  , to purchase new kitchen equipment.
• 
  Arthur’s Hometown Sausage & Barbecue
  
  , to purchase necessary marketing materials for a new food truck.
• 
  GiGi’s Bait & Tackle & Restaurant
  
  , to purchase a new point-of-sale system and restaurant seating.
• 
  Magnolia’s Catering
  
  , to manage marketing and promotional expenses.

According to data from Block Advisors’ ongoing “Small Business Recovery Series,” Black-owned businesses are seeing a disproportionate impact from pandemic-related factors, including more than half of Black business owners reporting a revenue decrease by 50% or more compared to only 37% of white business owners since March 2020. With nearly half (47%) of small business owners not optimistic about success in 2021, Block Advisors is doubling down on its small business focus through its partnership with the Urban League of Greater Kansas City to improve financial management and confidence among Black small businesses.

Business owners can learn more about the program by contacting Urban League of Greater Kansas City at www.ulkc.org.

About H&R Block

H&R Block, Inc. (NYSE: HRB) provides help and inspires confidence in its clients and communities everywhere through global tax preparation, financial products, and small-business solutions. The company blends digital innovation with the human expertise and care of its associates and franchisees as it helps people get the best outcome at tax time and better manage and access their money year-round. Through Block Advisors and Wave, the company helps small-business owners thrive with innovative products like Wave Money, a small-business banking and bookkeeping solution, and the only business bank account to manage bookkeeping automatically. For more information, visit H&R Block News or follow @HRBlockNews on Twitter.

About the Urban League of Greater Kansas City

The mission of the Urban League of Greater Kansas City is to enable African Americans and other disadvantaged populations to secure economic self-reliance, parity, power, and civil rights. The Urban League provides programs and services to:  ensure that youth are educated and equipped for economic self-reliance; help adults attain economic self-sufficiency through jobs, entrepreneurship, and wealth creation; assist in ensuring access to quality, affordable healthcare; remove barriers to equal participation in the economic mainstream; and advocate for racial equity and social justice. 

For Further Information

• Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.

Audio Webcast

The webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.

Dial-In Information

Live (U.S. / Canada): 1 (866) 940-5062
Live (International): 1 (409) 216-0618
Conference ID: 1924859

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended June 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:

Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]

BREA, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, which previously announced a definitive stock-for-stock reverse merger agreement with Net Element, Inc. (NASDAQ: NETE) in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company, announces today the hiring of Corry Davis as Vice President of Vehicle Integration and Homologation and GT Martinez as the Director of Certification & Homologation.

Both Davis and Martinez bring over 30 years of expertise in vehicle engineering and homologation experience and are positioned to accelerate Mullen’s manufacturing efforts as progress begins on the Mullen ONE EV Cargo Van at Mullen’s Advanced Manufacturing and Engineering Center (AMEC) in Tunica, Mississippi.  Both individuals will also play critical roles in the next stage of the Mullen FIVE EV Crossover, which will begin engineering validation in early 2022, as the FIVE production program starts.

With over 17 years of engineering and management experience, Davis is a highly accomplished and results-driven professional. Davis has held engineering leadership positions at multiple small vehicles and specialty manufacturers and has a specialized technical background in electric traction systems and vehicle integration. Having worked as a technical expert in component development and EV integration for automotive manufacturers in the United States, China, Korea and India.  Davis brings a large network of global industry experts, as well as a wealth of knowledge of electric drive system technology and full vehicle development, validation, and proven design methodologies.

Martinez is a homologation expert with decades of proven experience in certifying mobility vehicles and components /systems, thereby enabling companies to bring their concepts to market successfully. Martinez specializes in global safety standards and regulatory requirements and is skilled at developing internal regulatory metrics that drive and engage the engineering team while educating them on the importance of designing a global vehicle compliant product. In addition to his experience in global homologation, Martinez has vast experience in automated tooling design, manufacturing, procurement, and program management which has allowed for a greater ability to drive success within the project. Martinez will plan, implement, and manage all aspects of regulatory compliance at Mullen.

“We are working on delivering our first EV Cargo Vans to market in Q2 2022 and Corry and GT are key to our efforts,” said David Michery, CEO and chairman of Mullen Automotive. “Both Corry and GT bring a wealth of experience that complements our team.  I’m very pleased with our progress.  Everyone is focused in on bringing the Mullen ONE EV Cargo Van to market.  Our goal is to be timely and efficient with our EV products while also being fiscal responsible for our shareholders and customers.” 

Mullen will unveil its very first electric vehicle, the FIVE Crossover, in less than a month at the upcoming LA Auto Show on Nov. 17, 2021. Mullen will continue to display multiple variants of the FIVE model while also showcasing powertrain, battery, and charging technologies in the South Hall during the consumer days of the show, Nov. 19-28, 2021.

Designed, engineered, and manufactured entirely in the USA, the Mullen FIVE is built on an EV Crossover skateboard platform with multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience. Learn more about the Mullen FIVE at MullenUSA.com.

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the Company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Forward-Looking Statements

This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, often signify forward-looking statements. These forward-looking statements include, without limitation, statements relating to the reverse merger, the Nasdaq approval process and the proposed debut date of the Mullen FIVE (formerly MX-05) midsize crossover. These forward-looking statements are, by their nature, subject to significant risks and uncertainties.

Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements, including factors beyond the Company’s control. As a result of these and other risks, uncertainties and assumptions, forward-looking events and circumstances discussed herein might not occur in the way the Company expects or at all. Accordingly, readers should not place reliance on any forward-looking information or statements. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. All forward-looking statements herein are qualified by reference to the cautionary statements set forth in this section.

Contact:

Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com

For more information, please visit https://www.mullenusa.com/.

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

Attachments

• Corry Davis
• GT Martinez

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 4, 2021, to provide a business update and review the company’s financial results for the third quarter ended September 30, 2021.

To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13723976. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay^TM (odevixibat), was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.  

Media Contact: 
Colleen Alabiso, 857-356-3905, [email protected]
Lauren Sneider, 857-300-1737, [email protected]

Investor Contact: 
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578  

MADRID, Spain and MEXICO CITY, Oct. 28, 2021 (GLOBE NEWSWIRE) — Codere Online Luxembourg, S.A. announced that, on October 27, the U.S. Securities and Exchange Commission (“SEC”) declared effective the registration statement on Form F-4 which had previously been filed on August 13, 2021 and October 8, 2021, in connection with the previously announced proposed business combination of Codere Online, a leading online gaming and sports betting operator in Latin America, with DD3 Acquisition Corp. II (NASDAQ:DDMX) (“DD3”), a publicly traded special purpose acquisition company.

Consequently, DD3 has convened a special meeting of its stockholders to be held on November 18, 2021, at 11:00 a.m., Eastern time, at the offices of Greenberg Traurig, LLP, located at One Vanderbilt Avenue, New York, NY 10017, where the proposed business combination is expected to be voted upon. Once approved by DD3’s stockholders and subject to other customary closing conditions, it is currently expected that the business combination will be completed during the week following the special meeting.

About Codere Online

Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile application. Codere currently operates in its core markets of Spain, Italy, Mexico, Colombia and Panama and expects to start operating in the City of Buenos Aires (Argentina) in late 2021. Codere Online’s online business is complemented by Codere Group’s physical presence throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence in the region.

About Codere Group

Codere Group is a multinational group devoted to entertainment and leisure. It is a leading player in the private gaming industry, with four decades of experience and with presence in seven countries in Europe (Spain and Italy) and Latin America (Argentina, Colombia, Mexico, Panama, and Uruguay).

About DD3 Acquisition Corp. II

DD3 was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. DD3’s efforts to identify a prospective target business are not limited to a particular industry or geographic region. Learn more at https://www.dd3.mx/en/spac.

Additional Information about the Business Combination and Where to Find It

Codere Online Luxembourg, S.A. (“Holdco”), Servicios de Juego Online, S.A.U. (together with its consolidated subsidiaries upon consummation of the Proposed Business Combination, “Codere Online”), DD3 Acquisition Corp. II (“DD3”) and the other parties thereto have entered into a business combination agreement (the “Business Combination Agreement”) that provides for DD3 and Codere Online to become wholly-owned subsidiaries of Holdco (the “Proposed Business Combination”). In connection with the Proposed Business Combination, a registration statement on Form F-4 (the “Form F-4”) has been filed by Holdco with the U.S. Securities and Exchange Commission (“SEC”) that includes a proxy statement relating to DD3’s solicitation of proxies from DD3’s stockholders in connection with the Proposed Business Combination and other matters described in the Form F-4, as well as a prospectus of Holdco relating to the offer of the securities to be issued in connection with the completion of the Proposed Business Combination. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FORM F-4 AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. The definitive proxy statement/prospectus will be mailed to holders of record of DD3 common stock at the close of business on October 14, 2021, the record date established for voting on the Proposed Business Combination. Stockholders will also be able to obtain copies of such documents, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Codere Online Luxembourg, S.A., 7 rue Robert Stümper, L-2557 Luxembourg, Grand Duchy of Luxembourg.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including any statements as to Holdco’s, Codere Online’s, DD3’s or the combined company’s future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations, market size and potential growth opportunities, competitive position, expectations and timings related to commercial launches or the consummation of the Proposed Business Combination, potential benefits of the Proposed Business Combination and PIPE investments, technological and market trends and other future conditions, are forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Holdco’s, Codere Online’s, DD3’s and the combined company’s actual results may differ from their expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “likely,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Holdco’s, Codere Online’s and DD3’s expectations with respect to the timing of the completion of the Proposed Business Combination.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Most of these factors are outside Holdco’s, Codere Online’s and DD3’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the Business Combination Agreement; (2) the outcome of any legal proceedings that may be instituted against Holdco, Codere Online and/or DD3 following the announcement of the Business Combination Agreement and the transactions contemplated therein; (3) the inability to complete the Proposed Business Combination, including due to failure to obtain approval of DD3’s stockholders, certain regulatory approvals, or satisfy other closing conditions in the Business Combination Agreement; (4) the occurrence of any other event, change, or other circumstance that could cause the Proposed Business Combination to fail to close; (5) the impact of COVID-19 on Codere Online’s business and/or the ability of the parties to complete the Proposed Business Combination; (6) the inability to obtain and/or maintain the listing of Holdco’s ordinary shares or warrants on NASDAQ following the Proposed Business Combination; (7) the risk that the Proposed Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Proposed Business Combination; (8) the ability to recognize the anticipated benefits of the Proposed Business Combination, which may be affected by, among other things, competition, the ability of Codere Online and the combined company to grow and manage growth profitably, and retain its key employees; (9) costs related to the Proposed Business Combination; (10) changes in applicable laws or regulations; (11) the amount of redemptions by DD3’s stockholders in connection with the Proposed Business Combination; and (12) the possibility that Holdco, Codere Online or DD3 may be adversely affected by other economic, business and/or competitive factors. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in DD3’s most recent filings with the SEC, the Form F-4 and the definitive proxy statement/prospectus to be mailed to DD3’s stockholders in connection with the Proposed Business Combination. All subsequent written and oral forward-looking statements concerning Holdco, DD3, Codere Online, the combined company, the Proposed Business Combination or other matters and attributable to Holdco, Codere Online or DD3 or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of Holdco, Codere Online and DD3 expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

No Offer or Solicitation

This press release is not a proxy statement and does not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination. This press release also does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Participants in the Solicitation

Holdco, Codere Online and DD3 and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of DD3’s stockholders in connection with the Proposed Business Combination. Information regarding the names, affiliations and interests of DD3’s directors and executive officers is set forth in the final prospectus for DD3’s initial public offering filed with the SEC on December 10, 2020, as well as in other documents DD3 has filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of DD3’s stockholders in connection with the Proposed Business Combination is set forth in the Form F-4. Information concerning the interests of Holdco’s, Codere Online’s and DD3’s participants in the solicitation, which may, in some cases, be different than those of Holdco’s, Codere Online’s and DD3’s equity holders generally, is also set forth in the Form F-4. Shareholders, potential investors and other interested persons should read carefully the Form F-4 and the definitive proxy statement/prospectus before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

Contacts:

Investors

Ryan Lawrence, ICR
[email protected]
332-242-4321

Guillermo Lancha, Codere
[email protected]
(+34)-628-928-152

Media

Brian Ruby, ICR
[email protected]
203-682-8268

FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors. Dr. Paya will also serve as the Board Chair. Kurt von Emster, a longtime director who served as Interim Chair, will remain on the board.

“We are pleased to have Carlos and Michael join our board of directors to help us scale and advance our business to deliver next-generation vaccines, including VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV) candidate,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “Carlos, our new Chair, and Michael bring deep biopharmaceutical and vaccine expertise and will provide strategic insights across many aspects of our business, including R&D, commercialization, supply chain and manufacturing, as they have done for numerous companies.”

“Vaxcyte is working to bring transformative innovation to vaccine development with the potential to achieve what other approaches have been unable to deliver,” said Dr. Paya. “I’m pleased to join in their effort to advance novel and superior vaccines for some of the most common and deadly infectious diseases worldwide, including pneumococcal disease for which the need for broader-spectrum vaccines continues to be critical.”

Dr. Kamarck added, “Vaxcyte’s VAX-24 was designed to address the need for a PCV that can offer broader protection to prevent pneumococcal disease. As this program advances into clinical development, I look forward to sharing my knowledge about the worldwide commercialization and supply of vaccines, including PCVs.”

About Carlos Paya

Dr. Paya’s esteemed career spans over 30 years as a leading physician-scientist in immunology and a senior executive in the biopharmaceutical industry. He has broad leadership expertise in R&D, commercial readiness and product launches. Dr. Paya currently holds a number of board positions and serves as the Board Chairman for Fluidigm and Highlight Therapeutics. Most recently, Dr. Paya served as the CEO and President of Immune Design Corp., as they advanced their dual platforms focused on vaccine adjuvants and cancer immunotherapies, culminating in the company’s acquisition by Merck. Previously, he was the President of Elan Pharmaceuticals responsible for the Biopharmaceutical unit focused on neuroscience. In this role, he partnered with Biogen Idec to support the global marketing and sales strategy for Tysabri^®. Dr. Paya spent a number of years at Eli Lilly in roles of increasing responsibility, including Global Head for the Diabetes and Endocrine Franchise. He started his career in academics as a Professor of Medicine, Immunology and Pathology at the Mayo Medical School. During his tenure at the Mayo Clinic, Dr. Paya served at the Vice Dean for the Clinical Investigation Program. Dr. Paya has a M.D. and Ph.D. from Complutense University of Madrid.

About Michael Kamarck

Dr. Kamarck’s career in biopharmaceuticals spans over 35 years and includes senior executive positions at multiple leading pharmaceutical companies, as well as extensive expertise in product development and manufacturing. He is a global authority on the scale-up and commercialization of pneumococcal conjugate vaccines. He is the Chairman of the Sanofi Biotech Advisory Council, providing strategic guidance to advance Sanofi’s biologicals business. Dr. Kamarck recently retired as Chief Technology Officer for Vir Biotechnology, Inc., following more than four years leading a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19 (sotrovimab), influenza and hepatitis B. Previously, Dr. Kamarck was the Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply as a member of the Wyeth Management Team. While with Wyeth, he was responsible for establishing a global biotechnology network of more than 10,000 employees to develop and manufacture numerous blockbuster products, including building the manufacturing facilities to deliver the global supply of Prevnar 13^®. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including Senior Vice President of Operations for Bayer Biologicals. He has authored more than 50 peer-reviewed publications and has 20 issued patents. Dr. Kamarck received his B.A. from Oberlin College and his Ph.D. in biochemistry from Massachusetts Institute of Technology.

About Vaxcyte

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF^TM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum PCV being developed for the prevention of invasive pneumococcal disease. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the benefit of Vaxcyte’s vaccine candidates; the process and timing of anticipated future development of Vaxcyte’s vaccine candidates; the ability of Vaxcyte to scale manufacturing and business activities; and other statements that are not historical fact. The words “believe,” “could,” “expect,” “may,” “potential,” “should,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.

Contacts:

Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
[email protected]

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
[email protected]